Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025Biochemical Society TransactionsOpen Access

PROTACs in cancer immunotherapy: a minireview

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJohannes KöckenbergerSCS. CindyECEllen T. Chang

Discussion

Loading...

Member takes

Overview

Minireview highlights how protacs enhance immune response in cancer treatment, suggesting potential advancements.

Key Points

  • Protacs can improve cancer immunotherapy by enhancing immune responses and reducing immune suppression.
  • Preclinical studies demonstrate that protacs can promote major histocompatibility complex I ligandome changes.
  • Targeting protein degradation via protacs enables the inhibition of challenging protein interactions.
  • Limited response rates of current therapies underline the urgent need for novel strategies like protacs.

Cite This Study

Köckenberger et al. (2025) studied this question.

synapsesocial.com/papers/68de6f3183cbc991d0a2216ehttps://doi.org/10.1042/bst20253065
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities2025
  2. 2Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions2025
  3. 3Nanotechnology-Based Strategies for Overcoming Clinical Limitations of PROTACs in Cancer Therapy2025
  4. 4PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte2025
  5. 5Molecular erasers: Reprogramming cancer immunity through protein degradation2025